Brief: Cingulate Inc. Reports First Quarter 2023 Financial Results And Provides Clinical And Business Update
Cingulate Inc CING.O :
* . REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND
PROVIDES
CLINICAL AND BUSINESS UPDATE
* HAS OBTAINED AN ADDITIONAL $3 MILLION OF DEBT FINANCING
* QTRLY LOSS PER SHARE $0.35
* Q1 EARNINGS PER SHARE VIEW $-0.34 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX35nChR
Further company coverage: CING.O
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)